23andMe will now develop drugs without its chief drug developer

Richard Scheller, a veteran of Genentech, joined 23andMe in 2015 just as the consumer genetics company was embarking on the process of developing therapies of its own. Now 23andMe will have to manage without him.

Scheller left his post as chief scientific officer, the company confirmed, and will now spend his time as a chairman of R&D at BridgeBio Pharma while sitting on some biotech boards. In the meantime 23andMe’s head of therapeutics will take on Scheller’s duties but not his title, the company said.

Read more.